Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof

Inventors

Cook, Charles M. • Fu, Jiping • HE, Yigang • Lou, Yan • Chen, Rongzhen • Dong, Yan

Assignees

Nikang Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12415779-B2

Patent

Publication Date

2025-09-16

Expiration Date


Abstract

The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.

Core Innovation

The disclosure relates to an amine solvate of a fluorinated benzonitrile (Compound 1), wherein the amine is selected from defined monoamine or diamine classes, particularly the diethylamine solvate. It describes crystalline Form B of the diethylamine solvate characterized by an X-ray powder diffraction pattern with peaks at 13.8 and 21.3 2Θ. The amine solvate provides a purification route for conversion to crystalline Form A.

The purification route removes synthesis impurities from Compound 1 without column chromatography and provides a scalable process. Solid compositions comprise the diethylamine solvate and unsolvated Compound 1 within defined weight ratios. Compound 1 serves as an HIF-2Α inhibitor for proposed treatment of cancer and non-cancer diseases, including combination use with anticancer agents. Operational details regarding preparation are omitted: [procedural detail omitted for safety].

Claims Coverage

The claims identify five independent claims covering an amine solvate, a crystalline form, two preparation processes, and a solid composition.

Amine solvate of the fluorinated benzonitrile

The claim covers an amine solvate of the specified fluorinated benzonitrile compound, wherein the amine is selected from defined monoamine or diamine structural classes.

Crystalline Form B of the diethylamine solvate

The claim covers crystalline Form B of the diethylamine solvate, characterized by an X-ray powder diffraction pattern comprising peaks at 13.8 and 21.3 2Θ, subject to the stated positional tolerance.

Process for preparing an amine solvate

The claim covers a process for preparing and isolating a solid amine solvate of the specified compound, comprising forming a mixture containing the solvate. [procedural detail omitted for safety]

Process for preparing crystalline Form B

The claim covers a process for preparing and isolating crystalline Form B of the diethylamine solvate, characterized by the stated X-ray powder diffraction peaks. [procedural detail omitted for safety]

Solid composition of the solvate and Compound 1

The claim covers a solid composition comprising the diethylamine solvate and the corresponding unsolvated compound, with their weight ratio ranging from about 1:9 to about 1:0.001.

Together, the five independent claims cover the amine solvate, its Form B crystalline form, processes for preparing the solvate and Form B, and a solid composition containing the solvate and unsolvated compound.

Stated Advantages

The amine-solvate route is described as a scalable purification route that removes synthesis impurities without column chromatography.

Examples report crystalline Form A at 99.9% HPLC purity, 100% ee, and 93.5% yield.

Documented Applications

Compound 1 is identified as an HIF-2Α inhibitor for proposed treatment of cancer and non-cancer diseases.

Combination use of Form A Compound 1 with anticancer agents, including immune-checkpoint inhibitors, anticancer vaccines, and immune-modulatory therapies.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.